XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Finite Lived Intangible Assets [Line Items]        
Amortization expense $ 425,107 $ 425,107 $ 1,275,322 $ 1,275,322
Amortization of license agreements remainder of fiscal year 2018 425,108   425,108  
Amortization of license agreements in 2019 1,700,429   1,700,429  
Amortization of license agreements in 2020 1,700,429   1,700,429  
Amortization of license agreements in 2021 1,700,429   1,700,429  
Amortization of license agreements in 2022 1,700,429   1,700,429  
Amortization of license agreements in 2023 1,700,429   1,700,429  
Amortization of license agreements, thereafter 10,261,864   $ 10,261,864  
Novartis | Licensing Agreement        
Finite Lived Intangible Assets [Line Items]        
Amortization period of intangible assets     21 years  
Finite-lived intangible assets, accumulated amortization 494,684   $ 494,684  
Novartis | Patents        
Finite Lived Intangible Assets [Line Items]        
Amortization period of intangible assets     14 years  
Finite-lived intangible assets, accumulated amortization $ 5,173,413   $ 5,173,413